Beta Blocker Interruption After Uncomplicated Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3700 participants.

Also called NCT03498066

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,700 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03498066
Other papers using this trial's data
  • Beta-Blocker Interruption or Continuation after Myocardial Infarction The New England journal of medicine, 2024-10-10 DOI, PubMed 39213187

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03498066. Randomized; no masking; primary purpose treatment. Start 2018-08-29 (actual); primary completion 2023-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Beta Blocker Interruption After Uncomplicated Myocardial Infarction
Acronym
AβYSS
Intervention (Drug)
Beta-blockers withdrawal
Intervention (Drug)
Continuation of the Betablockers (βB) treatment
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Groupe Hospitalier Pitie-Salpetriere (class: other)

Record details

Record id
cardio:ct-nct03498066
Content hash
7c373ebd73993c7f8c0797ba4ae0163c60b562c83500d2b6698a49d6d812ac3d